Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01442779 | Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis | PHASE2 | COMPLETED | 18 | — | — | Sep 1, 2000 | May 1, 2007 | Apr 20, 2012 | 1 | United States |
Disease progression was determined by comparing results of the High Resolution Computed Tomography(HRCT) and pulmonary function at one year to the baseline HRCT \& pulmonary function. The same radiologist did the comparsion for all subjects.
| Name | Type | Description |
|---|---|---|
| Interferon alpha oral lozenge | DRUG | dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year |
Inclusion Criteria: * The only subjects to be included in this study are those diagnosed with Idiopathic Pulmonary Fibrosis with diagnosis based on the criteria published by the American Thoracic Society in the International Consensus Statement. 1. Exclusion of other known causes of interstitial...